Purchase Order 36C26122P0736
- Not listed
- This is a $93,341.96 firm fixed-price purchase order contract awarded by the U.S. Department of Veterans Affairs (VA) to Accredo Health Group, Inc., a for-profit pharmacy benefit management company. The contract is for the specialty pharmaceutical Tyvaso, which is used to treat pulmonary arterial hypertension. This contract is part of Accredo Health Group's ongoing work supporting the VA's Veterans Integrated Service Network (VISN) 21 with the distribution of specialty medications. The...
- This is a firm fixed-price purchase order contract awarded by the Department of Veterans Affairs' Veterans Integrated Service Network 21 to Accredo Health Group, Inc., a for-profit pharmacy benefit management company, for the delivery of the specialty pharmaceutical Tyvaso. The total ceiling value of the contract is $81,342.18, with a period of performance through September 30, 2022. Accredo Health Group, Inc. is a key distributor of complex and high-value medications, primarily serving the...
- This is a firm fixed-price purchase order contract awarded by the U.S. Department of Veterans Affairs (VA) to Accredo Health Group, Inc., a for-profit pharmacy benefit management company that specializes in specialty pharmaceutical services. The contract, valued at $75,576.09, is for the delivery of Uptravi medicine to support the VA's Veterans Integrated Service Network (VISN) 6. The contract does not have a set-aside designation and was awarded on October 27, 2020, with a completion date of...
- Accredo Health Group, Inc. was awarded a firm fixed price purchase order without set-aside by the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 21. The order is for the delivery of TYVASO to the Palo Alto, California location, with a potential value of $47,594.01 and completion by May 22, 2023. As a prime contractor supporting the VA through its national pharmaceutical contracts, Accredo Health Group will distribute this specialized pulmonary...
- This firm fixed-price purchase order was awarded by the Department of Veterans Affairs (VA) Veterans Health Administration (VHA) Veterans Integrated Service Network 16 to Accredo Health Group, Inc., a for-profit pharmacy benefit management company, to provide the specialty pharmaceutical drug Uptravi-Selexipag. The $144,743.29 contract has a completion date of March 17, 2022 and supports the VHA's distribution of critical medications to treat pulmonary arterial hypertension for patients and...
- This is a federal purchase order awarded by the U.S. Department of Veterans Affairs (VA) to Accredo Health Group, Inc., a specialty pharmacy services provider, for the supply of TYVASCO MEDICATION 0.6MG REFILL KITS. The $14,693.72 firm fixed-price contract has an ultimate completion date of October 9, 2024. Accredo, a subsidiary of Express Scripts, is a prime contractor that specializes in distributing complex and costly drugs used to treat chronic conditions, particularly in support of the VA's...
- This firm fixed-price purchase order, valued at $8,906.37, was awarded by the National Institutes of Health (NIH) Clinical Center to Accredo Health Group, Inc., a specialty pharmacy services provider. The contract is for the delivery of specific medications, such as Uptravi, Tyvaso, and Oxervate, to support treatment programs for the Veterans Health Administration (VHA). Accredo is a subsidiary of Express Scripts and has an established role as a key pharmaceutical distributor in the VA's...
- This is a federal contract award to Accredo Health Group, Inc., a prime contractor, by the Department of Veterans Affairs (VA) Veterans Health Administration (VHA) Veterans Integrated Service Network 21. The award is for the specialty medication UPTRAVI, with a potential value of $104,778.03 and a completion date of September 30, 2021. The contract is a firm fixed price purchase order with no set-aside designation. Accredo Health Group, a for-profit organization, provides specialty pharmacy...
- This is a firm fixed-price purchase order awarded by the U.S. Department of Veterans Affairs (VA) to Accredo Health Group, Inc., a for-profit pharmacy benefit management company, for the delivery of the specialty pharmaceutical DUOPA. The $10,122.32 contract has a completion date of May 7, 2025 and was awarded on February 7, 2025 with no set-aside designation. Accredo Health Group, Inc., a subsidiary of Express Scripts, is a key distributor of complex and high-value medications, primarily...
- Accredo Health Group, Inc. was awarded a firm fixed price purchase order without set aside designation from the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 21. The order is for the delivery of UPTRAVI to locations in Palo Alto, California, with a potential value of $13,985.29 and an completion date of April 20, 2023. As a prime contractor, Accredo Health Group will utilize its specialty pharmacy services and distribution network to directly...
This is a firm fixed-price purchase order contract awarded by the U.S. Department of Veterans Affairs (VA) to Accredo Health Group, Inc., a for-profit pharmacy benefit management company. The contract, valued at $94,899.21, is for the delivery of the drug Tyvaso, which is used to treat pulmonary arterial hypertension. The contract is not associated with a larger contract vehicle and does not have a set-aside designation. Accredo Health Group, Inc. is the prime contractor and there are no major subcontractors mentioned. The contract was awarded on March 10, 2022, with an ultimate completion date of September 30, 2022. Accredo Health Group, Inc. is a key distributor of complex and high-value medications, primarily serving the healthcare needs of veterans through the VA's Veterans Integrated Service Networks (VISNs).
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $94.9k | 3/10/22 |